1 - Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt
2 - Department of Immunology, National Medical and Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
3 - Primary Immunodeficiency Unit, Allergy and Immunology Division, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
4 - Department of Pediatrics, Faculty of Medicine, Kuwait University, Allergy and Clinical Immunology Unit, Al-Sabah Hospital, Kuwait City, Kuwait
5 - Immunology Unit Hospital de Nin~os Ricardo Gutierrez and CIC (Clinical Immunology Center), CABA, Buenos Aires, Argentina
6 - Department of Immunology, Institut Pasteur d’Algerie, Faculty of Medicine, Algiers, Algeria
7 - Clinical Immunology Unit, P1, Ibn Rushd Hospital, Laboratoire d’Immunologie Clinique, Inflammation et Allergie LICIA and Medicine and Pharmacy Faculty of Hassan II University, Casablanca, Morocco
8 - University Department of Pediatrics, Unit of Immune and Infectious Diseases, Childrens' Hospital Bambino Gesù, “University of Rome Tor Vergata”, Rome, Italy
9 - Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo – Sp, Brazil
10 - Division of Pediatric Infectious Diseases and Center for Infectious Diseases Research, Department of Pediatrics and Adolescent Medicine, American University of Beirut, Beirut, Lebanon
11 - Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada
12 - Ankara University School of Medicine, Department of Pediatric Immunology and Allergy, Ankara, Turkey
13 - The Royal Hospitals & Queen's University Belfast, United Kingdom
14 - Paediatric Infectious Diseases Unit, Red Cross War Memorial Children's Hospital and the Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa
15 - The Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico
16 - Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt q Primary Immunodeficiency Research Lab, Ghent University, Belgium
17 - Centre for Primary Immunodeficiency, Department of Pediatric Pulmonology and Immunology, Ghent University Hospital, Belgium
18 - Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, University of Khartoum, Sudan
19 - Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
20 - Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
21 - Pediatric Immunopathology and Allergology Unit, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy
22 - Primary Immunodeficiencies Unit, Hospital Dona Estefa^nia, Centro Hospitalar de Lisboa Central and CEDOC Nova Medical School, Lisboa, Portugal
23 - Pediatric Immuno-hematology Unit, Bone Marrow Transplantation Center, University Tunis El Manar, Faculty of Medicine, Tunis, Tunisia
24 - Department of Medicine and Sciences of Aging, University “G. d’Annunzio” of Chieti-Pescara, Italy
25 - LSU Health Sciences Center, New Orleans, LA, USA
26 - Department of Translational Medical Sciences, Section of Pediatrics, Federico II University, Naples, Italy
27 - Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili of Brescia, Brescia, Italy
28 - Department of Pediatric and Child Health, Aga Khan University Hospital, Karachi, Pakistan
29 - Department of Pediatric Hematology Oncology, Super Speciality Pediatric Hospital and PG Teaching Institute, Noida, India
30 - Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, and Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
31 - Federal University of Parana, Curitiba, Brazil
32 - Division of Allergy and Clinical Immunology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA
33 - Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Seville, Spain
34 - Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
35 - Rare Diseases Center, Children's Hospital and Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
36 - Department of Pediatrics and Chief, Allergy Immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
37 - Paediatric Institute Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia
38 - Department of Allergy and Immunology, The Royal Children's Hospital Melbourne, Australia
39 - Murdoch Children's Research Institute, Melbourne, Australia
40 - The University of Melbourne, Australia
41 - Hospital HHA, Universidad de la Frontera, Temuco, Chile
42 - Department of Pediatric Infectious Diseases and Immunology, Shupyk National Medical Academy of Postgraduate Education and Center for Clinical Immunology, City Children's Hospital N1, Kiev, Ukraine
43 - Division of Allergy Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
- Publicado no World Allergy Organization Journal 12 (2019) 100018
Resumo: Background: X-linked agammaglobulinemia is an inherited immunodeficiency recognized since 1952. In spite of seven decades of experience, there is still a limited understanding of regional differences in presentation and complications. This study was designed by the Primary Immunodeficiencies Committee of the World Allergy Organization to better understand regional needs, challenges and unique patient features.
Metodos: A survey instrument was designed by the Primary Immunodeficiencies Committee of the World Allergy Organization to collect both structured and semi-structured data on X-linked agammaglobulinemia. The survey was sent to 54 centers around the world chosen on the basis of World Allergy Organization participation and/or registration in the European Society for Immunodeficiencies. There were 40 centers that responded, comprising 32 countries.
Resultados: This study reports on 783 patients from 40 centers around the world. Problems with diagnosis are highlighted by the reported delays in diagnosis>24 months in 34% of patients and the lack of genetic studies in 39% of centers Two infections exhibited regional variation. Vaccine-associated paralytic poliomyelitis was seen only in countries with live polio vaccination and two centers reported mycobacteria. High rates of morbidity were reported. Acute and chronic lung diseases accounted for 41% of the deaths. Unusual complications such as in- flammatory bowel disease and large granular lymphocyte disease, among others were specifically enumerated, and while individually uncommon, they were collectively seen in 20.3% of patients. These data suggest that a broad range of both inflammatory, infectious, and autoimmune conditions can occur in patients. The breadth of complications and lack of data on management subsequently appeared as a significant challenge reported by centers. Survival above 20 years of age was lowest in Africa (22%) and reached above 70% in Australia, Europe and the Americas. Centers were asked to report their challenges and responses (n 1⁄4 116) emphasized the diffi- culties in access to immunoglobulin products (16%) and reflected the ongoing need for education of both patients and referring physicians.
Conclusão: This is the largest study of patients with X-linked agammaglobulinemia and emphasizes the continued morbidity and mortality of XLA despite progress in diagnosis and treatment. It presents a world view of the successes and challenges for patients and physicians alike. A pivotal finding is the need for education of physicians regarding typical symptoms suggesting a possible diagnosis of X-linked agammaglobulinemia and sharing of best practices for the less common complications.
Palavras Chave: Agammaglobulinemia, Autoimmunity, Infection, Outcomes Immunoglobulin Therapy, XLA